替罗非班联合依达拉奉右莰醇对急性进展性脑梗死患者的治疗效果  

Treatment Effect of Tirofiban Combined with Edaravone and Dexamethasone on Patients with Acute Progressive Cerebral Infarction

作　　者：王满利 黄每芹[1] 张震[1] 李艾帆[2] 樊玉香 WANG Manli;HUANG Meiqin;ZHANG Zhen;LI Aifan;FANYuxiang(Neurological Intensive Care Unit,Zhengzhou First People's Hospital,Zhengzhou 450000,China;Department of Neurology,Zhengzhou First People's Hospital,Zhengzhou 450000,China)

机构地区：[1]郑州市第一人民医院神经重症监护室,河南郑州450000 [2]郑州市第一人民医院神经内科,河南郑州450000

出　　处：《临床医学工程》2024年第11期1337-1338,共2页Clinical Medicine & Engineering

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20190983)。

摘　　要：目的探讨替罗非班联合依达拉奉右莰醇治疗急性进展性脑梗死(APCI)患者的临床效果。方法将72例APCI患者根据治疗方式不同分为参照组(36例,采用替罗非班治疗)和研究组(36例,采用替罗非班联合依达拉奉右莰醇治疗),均连续治疗2周。比较两组的临床疗效、神经功能、日常生活能力以及不良反应发生率。结果研究组治疗总有效率为94.44%,明显高于参照组的75.00%(P<0.05)。治疗2周后,研究组NIHSS评分低于参照组,ADL评分高于参照组(P<0.05)。研究组治疗期间不良反应发生率为13.89%,与参照组的11.11%比较无统计学差异(P>0.05)。结论替罗非班联合依达拉奉右莰醇可明显改善APCI患者的神经功能和日常生活能力,疗效确切且安全可靠,值得临床推广。Objective To explore the clinical effect of tirofiban combined with edaravone and dextrorphanol in the treatment of patients with acute progressive cerebral infarction(APCI).Methods 72 APCI patients were divided into reference group(36 cases,treated with tirofiban)and study group(36 cases,treated with tirofiban combined with edaravone and dextrorphan)according to different treatment methods.Both groups were treated continuously for 2 weeks.The clinical efficacy,neurological function,daily living ability and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 94.44%,higher than 75.00%in the reference group(P<0.05).After 2 weeks of treatment,the NIHSS score of the study group was lower than that of the reference group,and the ADL score was higher than that of the reference group(P<0.05).The incidence of adverse reactions during treatment in the study group was 13.89%,which had no statistical difference with 11.11%in the reference group(P>0.05).Conclusions Tirofiban combined with edaravone and dextrorphan can significantly improve the neurological function and daily living ability of APCI patients,has definite efficacy and is safe and reliable,which is worthy of clinical promotion and application.

关 键 词：急性进展性脑梗死 替罗非班 依达拉奉右莰醇 临床疗效 不良反应 

分 类 号：R743.33[医药卫生—神经病学与精神病学]